Zentalis Pharmaceuticals, Inc.
ZNTL
$1.77
-$0.04-2.21%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.36% | 17.46% | 7.72% | 17.96% | 11.20% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.07% | 13.90% | 8.51% | 11.73% | 11.25% |
| Operating Income | 11.99% | 3.79% | 8.79% | -11.73% | -11.25% |
| Income Before Tax | 37.64% | 32.10% | 9.09% | -23.29% | -23.69% |
| Income Tax Expenses | 129.90% | 130.02% | -43.65% | -28.14% | -1,752.00% |
| Earnings from Continuing Operations | 37.37% | 31.75% | 9.18% | -23.28% | -23.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -52.38% | -67.71% | -47.89% | -62.87% | -68.18% |
| Net Income | 37.37% | 31.73% | 9.15% | -23.39% | -23.44% |
| EBIT | 11.99% | 3.79% | 8.79% | -11.73% | -11.25% |
| EBITDA | 12.02% | 3.77% | 8.81% | -11.82% | -11.26% |
| EPS Basic | 45.69% | 43.02% | 22.09% | -0.39% | 1.36% |
| Normalized Basic EPS | 40.02% | 37.21% | 36.01% | 13.12% | 10.93% |
| EPS Diluted | 45.69% | 43.02% | 22.11% | -0.47% | 1.28% |
| Normalized Diluted EPS | 40.00% | 37.19% | 35.99% | 13.12% | 10.93% |
| Average Basic Shares Outstanding | 14.09% | 20.58% | 21.21% | 23.76% | 25.57% |
| Average Diluted Shares Outstanding | 14.21% | 20.71% | 21.34% | 23.76% | 25.57% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
